143 related articles for article (PubMed ID: 17671082)
1. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice.
Emmenegger U; Shaked Y; Man S; Bocci G; Spasojevic I; Francia G; Kouri A; Coke R; Cruz-Munoz W; Ludeman SM; Colvin OM; Kerbel RS
Mol Cancer Ther; 2007 Aug; 6(8):2280-9. PubMed ID: 17671082
[TBL] [Abstract][Full Text] [Related]
2. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2001 Jun; 61(11):4437-44. PubMed ID: 11389073
[TBL] [Abstract][Full Text] [Related]
3. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
Wu J; Waxman DJ
Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
[TBL] [Abstract][Full Text] [Related]
4. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
Huang Z; Raychowdhury MK; Waxman DJ
Cancer Gene Ther; 2000 Jul; 7(7):1034-42. PubMed ID: 10917206
[TBL] [Abstract][Full Text] [Related]
5. Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy.
Schwartz PS; Chen CS; Waxman DJ
Cancer Gene Ther; 2003 Aug; 10(8):571-82. PubMed ID: 12872138
[TBL] [Abstract][Full Text] [Related]
6. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.
Shaked Y; Emmenegger U; Francia G; Chen L; Lee CR; Man S; Paraghamian A; Ben-David Y; Kerbel RS
Cancer Res; 2005 Aug; 65(16):7045-51. PubMed ID: 16103050
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model.
Chen CS; Jounaidi Y; Su T; Waxman DJ
Cancer Gene Ther; 2007 Dec; 14(12):935-44. PubMed ID: 17853921
[TBL] [Abstract][Full Text] [Related]
8. Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors.
Huang Z; Waxman DJ
Cancer Gene Ther; 2001 Jun; 8(6):450-8. PubMed ID: 11498765
[TBL] [Abstract][Full Text] [Related]
9. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.
Emmenegger U; Man S; Shaked Y; Francia G; Wong JW; Hicklin DJ; Kerbel RS
Cancer Res; 2004 Jun; 64(11):3994-4000. PubMed ID: 15173013
[TBL] [Abstract][Full Text] [Related]
10. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
Emmenegger U; Morton GC; Francia G; Shaked Y; Franco M; Weinerman A; Man S; Kerbel RS
Cancer Res; 2006 Feb; 66(3):1664-74. PubMed ID: 16452226
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide administered repeatedly to the male rat and as a single dose to the female rat. Its effects on hepatic and pulmonary P450 and associated enzymes.
Angley MT; Sansom LN; Stupans I
Xenobiotica; 1995 Nov; 25(10):1051-62. PubMed ID: 8578761
[TBL] [Abstract][Full Text] [Related]
12. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.
Emmenegger U; Francia G; Chow A; Shaked Y; Kouri A; Man S; Kerbel RS
Neoplasia; 2011 Jan; 13(1):40-8. PubMed ID: 21245939
[TBL] [Abstract][Full Text] [Related]
13. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse.
Pass GJ; Carrie D; Boylan M; Lorimore S; Wright E; Houston B; Henderson CJ; Wolf CR
Cancer Res; 2005 May; 65(10):4211-7. PubMed ID: 15899812
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
Chen L; Waxman DJ; Chen D; Kufe DW
Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
[TBL] [Abstract][Full Text] [Related]
15. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
Yu LJ; Drewes P; Gustafsson K; Brain EG; Hecht JE; Waxman DJ
J Pharmacol Exp Ther; 1999 Mar; 288(3):928-37. PubMed ID: 10027828
[TBL] [Abstract][Full Text] [Related]
16. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.
Chen CS; Doloff JC; Waxman DJ
Neoplasia; 2014 Jan; 16(1):84-96. PubMed ID: 24563621
[TBL] [Abstract][Full Text] [Related]
17. Low-dose metronomic delivery of cyclophosphamide is less detrimental to granulosa cell viability, ovarian function, and fertility than maximum tolerated dose delivery in the mouse.
Dynes J; Osz K; Hooper A; Petrik J
Biol Reprod; 2017 Sep; 97(3):449-465. PubMed ID: 29024988
[TBL] [Abstract][Full Text] [Related]
18. Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector.
Ichikawa T; Petros WP; Ludeman SM; Fangmeier J; Hochberg FH; Colvin OM; Chiocca EA
Cancer Res; 2001 Feb; 61(3):864-8. PubMed ID: 11221871
[TBL] [Abstract][Full Text] [Related]
19. A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition.
Gu J; Chen CS; Wei Y; Fang C; Xie F; Kannan K; Yang W; Waxman DJ; Ding X
J Pharmacol Exp Ther; 2007 Apr; 321(1):9-17. PubMed ID: 17218484
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
